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“I have the simplest of tastes. I am always satisfied with the best.”
– Oscar Wilde
How do you capture an idea, shape it, and then bring it into the world? Of his many talents, 
this ability was a fundamental characteristic of Mihai Gheorghiade. A quick glance through 
PubMed confirms his prodigious output, likely to overwhelm any novice or even expert 
scholar. His contribution to heart failure, especially acute heart failure (AHF), is profound, 
He authored several major concepts in acute heart failure, disseminated further by his 
students. Most concepts remained indelibly linked to his name: Digoxin trials research(1–3), 
AHFS (acute heart failure syndromes) definition(4), hemodynamic congestion(5), 
hospitalized heart failure (HHF) (6), the vulnerable phase(7,8), neutral hemodynamic 
agents(9), registries(10–12) and pre-trial registries(13), the “6-axis model”(14) and then the 
“8-axis model”(15). His work shaped the field of AHF.
Reviewing the chronologic history of his tremendous scientific output is best described as a 
review of a best-selling novel: a brilliance and force of thought, a literary juggernaut. You 
might not agree, but you read, you listened.
Unfortunately, there is no PubMed of his life; the way he lived, the larger than life 
personality that exuded energy and an inhuman devotion to his work. The impact he had on 
his students, residents, fellows, colleagues, and friends extends far beyond the authorship 
byline. While the compendium that follows shares a brief review of some of the most 
important concepts authored by Mihai, we wanted to share a bit about his life.
Ask anyone who knew him and they will tell you one, if not many, Mihai stories. These are 
special, treasured and quickly identify those who knew him well. He challenged you, yet at 
the same time was very clear he didn’t have all the answers. But he always had a question. 
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However, the best were the stories of his own life, his struggles as an immigrant, his 
realization that clinical research was where he wanted to make his mark. For me, the stories 
came later in his life. It is when others who knew him gather together, telling a more 
chronologic tale, that the picture became more complete. The stories are not about perfect 
though. Like all of us, he was not a perfect man. However, he was a brilliant man; besides, 
perfect men don’t exist and for certain, don’t change the world.
My story with Mihai begins in 2007. As I write this, I can see him; that smile, mustache, 
impeccably dressed, the accent, and the question: “what is acute heart failure?” He loved 
asking these types of questions. At first glance, it seems such an odd question or too broad. 
But once you knew him a bit more, you better understood the depth. What is acute heart 
failure? How do we define it? If we don’t share a common definition, how will we study it, 
build upon a common framework? One of his landmark papers, published in Circulation in 
2005, addresses this daunting question head on, becoming the definition of AHF most 
commonly used today. He was the single greatest influence on my academic career, the 
greatest mentor I ever had. To this day, when my wife and I celebrate our many blessings, 
we always raise a toast to Mihai.
Peter Pang
I knew him since 2005. In the beginning, he would call, usually very early in the morning, 
asking about the various manuscripts we had started. Our conversations were never in one 
language, rather a mélange of English, Romanian and Italian. In the last year, we talked 
every day, discussing a range of topics, from papers, history, the next economic crisis, 
friends and friendship, mentorship.
Papers frequently resulted from these long phone calls, when he dictated the structure and 
main ideas. I never had a written review; he was always very critical, constructive, keeping 
an excellent sense of humor. He told me: “Just imagine that you are the reviewer for this 
manuscript; probably you will reject it.” He was very eager to find simpler answers with 
potential clinical implications. He set “the patient first” in a world where other interests are 
first. Details mattered, telling me “the excellence is the sum of the small details.” He was 
committed to excellence and he disseminated it. He shaped my career and my way of 
thinking.
Ovidiu Chioncel
Early in my career, I joined a group of cardiologists at a HF meeting. I had never met Mihai 
before, and I was clearly the junior investigator in the room. At the first break, Mihai pulled 
me aside and spoke with the conviction he embodied so well; “You must speak up, all of 
these people in the room have no idea what happens in the first 6–12 hours of heart failure 
care. Don’t be afraid to tell them they are wrong – because they are. We need to change the 
landscape of current heart failure trials. You need to lead this discussion.” I remember going 
back to my seat and feeling unsure as to whether I should say anything. Once the discussion 
resumed, Mihai spoke up and said “We have this all wrong- these patients look much 
different when they present to the hospital. Sean, tell them how this really is.” And this 
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launched my long-standing relationship with Mihai. This first interaction was a good peek 
into what my collaboration with Mihai was like, and that was how many of our 
conversations proceeded over the next decade. Brief, challenging, and forward thinking best 
described our frequent discussions. Frequently I would receive a brief email: “call me” or 
“we need to talk”. I knew it was time for another tutorial. I will miss his mentorship, 
friendship and frequent challenges.
Sean Collins
One of the luckiest days of my career was during an annual heart failure meeting on Amelia 
Island in 2010. I was working in the lobby and saw Mihai pacing up and down the corridor. I 
did not know him well, but eventually, he sat down next to me. As we talked, I learned his 
car service was late and he needed to get to the airport. Such small-talk quickly morphed 
into an argument about vasodilator use in heart failure. He left when his car arrived but 
emailed me that night asking for my phone number. He called me the same night and we 
talked for a long time. I was surprised as to why he would give so much time and attention to 
the topic, especially so late at night. This was the beginning of my relationship with Mihai. 
At the time of his death, we had published over 100 papers together, several were in 
development stage, mentored several young investigators, and were involved in many other 
initiatives, and became best of friends. As I reflect on those two initial experiences – why 
was he so passionate about vasodilators and why is he taking time out late at night to talk 
about it – I came to realize that is who he was. I enjoyed 7 years of Mihai’s late night phone 
calls, fueled by his enthusiasm and passion for his work.
Javed Butler
For a man who loved writing, a defining characteristic few would believe: he couldn’t type. 
Ironically, this flaw may have been one of his greatest assets. It brought a natural 
cohesiveness for mentor and mentee. Documents did not evolve through a to and fro of track 
changes. Mentees spent time at his desk or on the phone with him. They articulated his 
passion into the manuscript, while simultaneously receiving irreplaceable one-on-one 
mentoring. He was never more enthusiastic than when supporting new collaborations 
between young minds in different countries.
Given his incredible scholarly output, only those who had the privilege to work side by side, 
day in, day out, were able to witness this characteristic. Imagine sitting side by side, 
discussing and writing concepts, sentences, reviewing older papers! For some, such a model 
would be fire and brimstone! But for me and countless others, a reflection of the 
apprenticeship model of medicine. If you want to learn, come sit by me, watch, listen, type, 
learn! These were not mere exercises; rather they shaped the relationship, taught both parties 
so much about each other. And you had to earn the time to type for him! Late evenings, 
weekend mornings…sometimes there would be a line of us waiting to sit in the chair to 
type! In retrospect, the outpouring of scholarly output seems the secondary outcome. A 
“Bravo!” from Mihai at the end of one of these sessions was the highest praise.
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While the data driven papers were the gold, it was the discussion section, the commentaries 
or editorials that was the art. Now was the time to dissect, to reflect, to set the stage, to 
strategize. The data was the data – interpreting the data was the lesson, and articulating the 
unmet need, critical next steps, and subsequent path forward was the goal for such 
documents. Don’t describe the current state, but tell the audience where we need to go, and 
then take them there.
Ultimately, for a brief, intense period, he was a like a second father to me. For 2 years, we 
talked every day, no matter where he was in the world, no matter the holiday. For those who 
knew him, it is an easy truth. Such time shapes a person, leaves an imprint. For example, his 
love of digoxin! And papers! And good suits, and fast cars and a respect for being so facile 
in so many languages. What he taught me, he taught all who had the privilege to work with 
him:
1. Be passionate about your work
2. Ask the important question and go after it!
3. Write, write, and write!
4. Clinical trials – the ultimate scientific experiment.
5. Earn and enjoy the very best life has to offer.
In the pages to follow are some of the many concepts on AHF from Mihai Gheorghiade. For 
all of us who knew him, we hope this provides a chance to glimpse of the person we all miss 
so very much.
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